TY - JOUR
T1 - Management of Gastroparesis
AU - Zheng, Ting
AU - Camilleri, Michael
N1 - Funding Information:
Dr Zheng has no relevant conflicts of interest to disclose. Dr Camilleri has received research grants from Takeda (felcise-trag) and Vanda (tradipitant), and grant R01-DK122280 from the National Institutes of Health for the study of gastroparesis.
Publisher Copyright:
© 2021 Gastro-Hep Communications, Inc.. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Gastroparesis is a gastrointestinal motility disorder characterized by nausea, vomiting, early satiation, postprandial fullness, bloating, and upper abdominal pain. The diagnosis requires documented delay in gastric emptying with an optimal test such as scintigraphy or stable isotope gastric emptying breath test in the absence of mechanical obstruction. The pathophysiologic mechanisms of gastroparesis are multifactorial, including antroduodenal hypomotility, pylorospasm, impaired gastric accommodation, and visceral hypersensitivity. The etiologies of gastroparesis are broad, but the most common subtypes are idiopathic, diabetic, and postsurgical. Less frequent etiologies are neurodegenerative disorder (Parkinson disease), myopathies (scleroderma, amyloidosis), and neoplastic syndrome. Symptoms of gastroparesis can be refractory and challenging to manage, leading to reduced quality of life and significant health care expenditure. This article introduces the epidemiology, clinical presentation, diagnosis, and differential diagnoses of gastroparesis, followed by a focused discussion on its management, including nutritional support, prokinetic and antiemetic agents, and emerging interventions directed at the pylorus. Robust sham-controlled trials are needed to evaluate the long-Term efficacy of gastric peroral endoscopic myotomy. A multidisciplinary approach with individualized strategies based on characterization of the pathophysiology is deemed necessary to enhance clinical outcomes.
AB - Gastroparesis is a gastrointestinal motility disorder characterized by nausea, vomiting, early satiation, postprandial fullness, bloating, and upper abdominal pain. The diagnosis requires documented delay in gastric emptying with an optimal test such as scintigraphy or stable isotope gastric emptying breath test in the absence of mechanical obstruction. The pathophysiologic mechanisms of gastroparesis are multifactorial, including antroduodenal hypomotility, pylorospasm, impaired gastric accommodation, and visceral hypersensitivity. The etiologies of gastroparesis are broad, but the most common subtypes are idiopathic, diabetic, and postsurgical. Less frequent etiologies are neurodegenerative disorder (Parkinson disease), myopathies (scleroderma, amyloidosis), and neoplastic syndrome. Symptoms of gastroparesis can be refractory and challenging to manage, leading to reduced quality of life and significant health care expenditure. This article introduces the epidemiology, clinical presentation, diagnosis, and differential diagnoses of gastroparesis, followed by a focused discussion on its management, including nutritional support, prokinetic and antiemetic agents, and emerging interventions directed at the pylorus. Robust sham-controlled trials are needed to evaluate the long-Term efficacy of gastric peroral endoscopic myotomy. A multidisciplinary approach with individualized strategies based on characterization of the pathophysiology is deemed necessary to enhance clinical outcomes.
KW - Gastric emptying
KW - gastric accommodation
KW - nutritional support
KW - prokinetics, gastric peroral endoscopic myotomy
KW - visceral hypersensitivity
UR - http://www.scopus.com/inward/record.url?scp=85126464596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126464596&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85126464596
SN - 1554-7914
VL - 17
SP - 515
EP - 525
JO - Gastroenterology and Hepatology
JF - Gastroenterology and Hepatology
IS - 11
ER -